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Objectives: To compare the efficacy and tolerability of
allopurinol 300–600 mg/day versus benzbromarone
100–200 mg/day used to attain a target serum urate
concentration (sUr) (0.30 mmol/l (5 mg/dl).
Methods: A randomised, controlled, open-label, multi-
centre trial in gout patients with renal function defined as
a calculated creatinine clearance >50 ml/min. Patients
were treated with 300 mg allopurinol or 100 mg
benzbromarone once a day (stage 1). If sUr (0.30 mmol/l
was not attained after 2 months, the dose was doubled to
allopurinol 300 mg twice a day or benzbromarone 200 mg
once a day (stage 2). The primary end point was treatment
success in either of the two stages, defined as clinical
tolerability and attainment of biochemical target sUr.
Results: Sixty-five patients were enrolled in stage 1; 36
received allopurinol and 29 received benzbromarone. Fifty-
five patients (85%) were analysed at stage 1: the success
rates were 8/31 (26%) and 13/25 (52%), respectively,
and the difference was 20.26 (95% CI from 20.486 to
20.005), p = 0.049. At stage 2, the success rates were
21/27 (78%) and 18/23 (78%), respectively, and the
difference was 20.005 (95% CI from 20.223 to 0.220),
p = 1.00. Two patients stopped receiving allopurinol and
three stopped receiving benzbromarone because of
adverse drug reactions.
Conclusions: Increasing the allopurinol dose from 300 to
600 mg/day and the benzbromarone dose from 100 to
200 mg/day according to the target sUr produced
significantly higher success rates (both 78% successful in
attaining sUr (0.30 mmol/l). No significant differences in
treatment success between benzbromarone and allopur-
inol were found after dose escalation.
Trial registration number: ISRCTN49563848).
Allopurinol is the drug of choice in the long-term
treatment of gout in the 2006 EULAR evidence-
based recommendations.1 Quite similar recommen-
dations are given by the British Society of
Rheumatology, with a remarkably lower biochem-
ical target for serum urate concentration (sUr; 0.30
vs 0.36 mmol/l).2 In order to reach the target sUr,
the EULAR recommendations advise titrating the
allopurinol dose up to a maximum of 900 mg/day.
However, historically a fixed dose of 300 mg/day is
mostly used in clinical research and clinical
practice.3 Data on clinical efficacy and tolerability
of urate-lowering treatment are scarce, especially
for higher than standard doses.4 In one study,
allopurinol 600 mg/day was given to 19 patients,
resulting in a mean (SD) sUr decrease of 44 (13)%
compared with baseline and 52% success in
attaining sUr (0.30 mmol/l.5 In a dose–response
study in patients with heart failure, sUr decreased
from 0.41 (0.11) mmol/l to 0.16 (0.06) mmol/l
when allopurinol 600 mg/day was used.6 In a
randomised controlled trial of benzbromarone
200 mg/day versus probenecid 2000 mg/day
(ISRCTN21473387, www.controlled-trials.com),
we found a decrease in sUr of 64 (9)% compared
with baseline, and 92% success in attaining sUr
(0.30 mmol/l.7
The goal of sUr-lowering treatment is to reduce
the sUr to below the threshold of supersaturation
to prevent any gouty attack by allowing the
dissolution of existing monosodium urate crystals
in the joints and to stop the deposition of new
crystals.8–13 The solubility of urate in joint fluids is
influenced by temperature, pH, concentration of
cations, level of articular dehydration and the
presence of nucleating agents such as insoluble
collagens, chondroitin sulphate and non-aggre-
gated proteoglycans.8 The occurrence of acute gout
attacks depends on the sUr attained and mechan-
ical stress, as joints affected by osteoarthritis may
be predisposed to attacks.9 10
According to the EULAR 2006 recommenda-
tions, the goal of sUr-lowering treatment is to
reach a target sUr of ,0.36 mmol/l (6.1 mg/dl).1
Historically, the target sUr is based on the
solubility of monosodium urate. For instance, the
threshold level of deposition of monosodium urate
is 0.36 mmol/l at 35uC and 0.27 mmol/l at 30uC.14
However, gout attacks mostly occur in the
extremities, where body temperature is lowest
and the solubility of monosodium urate is lowest.
It has been shown that recurrent gouty attacks are
more effectively prevented and that tophi dissolve
more quickly with a target sUr of ,0.30 mmol/l
(5.0 mg/dl) compared with levels of 0.30–
0.36 mmol/l.15–19 For this reason, the British
Guideline 2007 sets the sUr treatment goal for
patients with gout at (0.30 mmol/l.2
In order to obtain more evidence-based data, we
investigated the efficacy and tolerability of dose
escalation of allopurinol versus benzbromarone to
attain a target sUr of (0.30 mmol/l.
PATIENTS AND METHODS
This prospective, multicentre, open-label, rando-
mised controlled trial was carried out in successive
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previously untreated patients with gout recently diagnosed by a
rheumatologist. Eligibility criteria were: (1) a diagnosis of gout,
confirmed by microscopic evidence of urate crystals in punctate
from synovial fluid or peri-articular structures or the presence of
tophi; (2) no history of having used one of the study drugs; (3)
no relevant liver disease; (4) renal function defined as a
calculated creatinine clearance (cCrCl) >50 ml/min calculated
using the formula of Cockcroft and Gault; (5) an indication for
sUr-lowering treatment—presence of tophi or frequent attacks
(.2/year).20–23 Before the patients entered the study and after
each treatment period, liver function, serum creatinine and
cCrCl, sUr, urinary creatinine excretion and urinary urate
excretion on an unrestricted purine diet were measured. In
patients using allopurinol, serum oxipurinol concentrations
were also measured after each treatment period. Underexcretion
of urate was defined as urate clearance ,6.0 ml/min per
1.73 m2.24 This was calculated from the urinary volume
(converted into ml/min) 6 (urinary urate concentration/sUr)
and normalised for a body surface area of 1.73 m2.
Overproduction of urate was defined as urinary urate excretion
.6.0 mmol/day. Normal excretion of urate was defined as urate
clearance >6.0 ml/min per 1.73 m2 and urinary urate excretion
(6.0 mmol/day. Reported adverse events were checked for
causality by the Naranjo Causality Scale.25 Those classified as
doubtful were not included as adverse drug reactions in the
tolerability evaluation.
At the time of inclusion in the study, patients were assigned
an inclusion number by the rheumatologist (blinded) and
subsequently randomised to allopurinol or benzbromarone
treatment. A computer-generated central randomisation sche-
dule with a block size of six was used. Study recruitment and
follow-up were from July 2006 until December 2007.
Patients were given allopurinol 300 mg (several generic
brands) in a step-up dose scheme (100 to 200 to 300 mg/day,
dose raised every week) or benzbromarone 100 mg once a day
(Desuric; Prostrakan, Galashiels, UK). If treatment was toler-
ated but the treatment goal of sUr (0.30 mmol/l was not
reached after 2 months, the allopurinol dose was doubled to
300 mg twice a day and the benzbromarone dose to 200 mg
once a day. The dose interval of allopurinol was set at twice a
day at the higher dose because this is recommended in the
product information. Also, from a pharmacodynamic point of
view, administration twice a day yields higher serum trough
concentrations, which may result in greater enzyme inhibition.
Treatment was evaluated again after 2 months. If treatment
was not tolerated and the patient stopped the treatment, this
was categorised as a failure. If treatment was tolerated and the
target sUr was reached, this was categorised as a success.
Defined daily doses are allopurinol 400 mg/day and benzbro-
marone 100 mg/day.
Prophylaxis of gouty episodes with colchicine 0.5–1 mg/day
was prescribed until the target sUr was reached ((0.30 mmol/l);
Figure 1 Flow of participants through
each stage of the study. cCrCl, calculated
creatinine clearance.
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if colchicine was not tolerated, a non-steroidal anti-inflam-
matory drug could be prescribed as an alternative.
The primary end point was the percentage of patients who
tolerated the sUr-lowering medication and attained sUr
(0.30 mmol/l after stage 1 or stage 2. The secondary end
point was the relative decrease in sUr attained with each
treatment regimen.
Statistical analysis
A power calculation indicated that at least 22 patients were
needed for evaluation in each treatment arm to prove a
statistically significant difference between allopurinol and
benzbromarone (based on an estimated 55% success rate for
allopurinol 600 mg/day versus 90% for benzbromarone 200 mg/
day, a= 0.05, b= 0.20).5 7 We expected a loss to follow-up of
25%, rendering a minimum of 60 patients required for the
study. SPSS V15.0 and V16.0 for Windows were used for data
collection, data validation, data selection and statistical
analysis. The Student two-sided t test and Fisher–Boschloo
unconditional test were used to compare the effectiveness of
allopurinol and benzbromarone; 95% CIs of proportions were
calculated using binomial distribution, and 95% CIs of
differences of proportions using the Agresti–Caffo method.26 27
Normality was verified by Kolmogorov–Smirnov analysis.
p,0.05 was considered significant.
The study was approved by the medical ethical review board
of the participating hospitals, and written informed consent
was obtained from all participating patients.
RESULTS
Sixty-eight patients were enrolled in the study (fig 1). Three did
not meet the inclusion criteria (cCrCl was ,50 ml/min), leaving
sixty-five patients for analysis of baseline characteristics (table 1).
Thirty-six patients received allopurinol and 29 received benzbro-
marone. Fifty-five patients (85%) were eligible for analysis of stage
1 results and 50 patients (77%) for analysis of stage 1+2.
Table 2 and fig 2 give the results of stage 1 and 2. The
treatment target was reached in eight out of 30 patients (26%)
using allopurinol 300 mg/day; after the increase in dose to
600 mg/day, the overall treatment success was 21 out of 27
patients (78%). With benzbromarone 100 mg/day, the treat-
ment target was reached in 13 out of 25 patients (52%); after
the increase in dose to 200 mg/day, the overall treatment target
was reached in 18 out of 23 patients (78%). Two patients
stopped receiving allopurinol and three stopped receiving
benzbromarone because of adverse drug reactions (table 3).
No additional adverse drug reactions were reported after the
increase in doses of allopurinol and benzbromarone. At stage 1,
the success rates were 8/31 = 0.26 and 13/25 = 0.52; the
difference was 0.26 2 0.52 = 20.26 (95% CI from 20.486 to
20.005), p = 0.049. At stage 2, the success rates were
21/27 = 0.78 and 18/23 = 0.78; the difference was 20.005
(95% CI from 20.223 to 0.220), p = 1.00.
The mean (SD) reduction in sUr from baseline obtained with
allopurinol was 33 (13)% at a dose of 300 mg/day and 49 (14)%
at a dose of 600 mg/day. Increasing the allopurinol dose to
600 mg/day for patients above target sUr after stage 1 resulted
in an additional sUr decrease of 32 (16)% compared with that
produced by the 300 mg/day dose.
For benzbromarone, the reduction in sUr from baseline was
42 (15)% with the 100 mg/day dose and 46 (8)% with the
200 mg/day. Increasing the benzbromarone dose to 200 mg/day
in patients above target sUr after stage 1 resulted in an
additional sUr decrease of 29 (6)% compared with that produced
by the 100 mg/day dose.
DISCUSSION
This study showed that treatment success, defined as reaching
sUr (0.30 mmol/l, by administering allopurinol in patients
with cCrCl >50 ml/min is significantly increased from 29% to
78% by doubling the allopurinol dose to 600 mg/day (p,0.001).
Benzbromarone produced significantly greater treatment suc-
cess at the starting dose (stage 1) than allopurinol, as also
shown in previous trials.28 29 After dose escalation (stage 2),
there was no longer a significant difference in treatment success
between the two drugs.
The treatment success rate for allopurinol 300–600 mg/day
(78%) was higher than previously reported. Rundles et al5 found
a treatment success rate of 53% (95% CI 29% to 76%) in 19
patients using allopurinol 600 mg. Baseline sUr in these 19
patients (0.56 (0.11) mmol/l) was comparable to that in our
study. We may have obtained better results by using a twice-
daily dose scheme, in comparison with once daily used by
Rundles et al, as higher trough oxipurinol concentrations may
result in greater xanthine oxidase inhibition. Allopurinol is
approved for use up to 900 mg/day,2 and even better results
may be possible using this maximum dose. In the Netherlands, a
national guideline recommends a maximum dose of 700 mg
allopurinol/day.30
A treatment duration of 2 months may be considered too
short for treatment evaluation, especially in patients with poor
renal urate excretion and therefore longer serum urate half-life.
In subjects who do not have gout, the serum urate half-life is
Table 1 Details and clinical characteristics of the study participants
Allopurinol (n = 36)
Benzbromarone
(n = 29)
Age (years) 58.6 (12.3) 59.6 (11.3)
Male (%) 81 83





Body mass index (kg/m2) 29.4 (4.8) 30.5 (6.9)
cCrCl (%)
30–50 ml/min (3 excluded) (0 excluded)
50–80 ml/min 22 39
.80 ml/min 78 61
Research site (%)
Medisch Centrum Leeuwarden 28 24
Ziekenhuisgroep Twente 41 45
Medisch Spectrum Twente 31 31
Urate characteristics
sUr (mmol/l) 0.54 (0.09) 0.51 (0.08)
Range 0.39–0.83 0.34–0.70
uUr (mmol/day) 3.4 (1.3) 3.4 (1.3)
Range 1.5–7.7 1.3–6.3




Normal excretor 3 3
Overproducer 3 8
Data are mean (SD) or percentage, unless stated otherwise.
cCrCl, calculated creatinine clearance; sUr, serum urate; UrCl, urate clearance; uUr,
urate excreted in urine.
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,0.85 day.31 In patients with gout and severe underexcretion of
urate (urate clearance 1.5 ml/min; reference value is ,6 ml/min
per 1.73 m2), we therefore estimated that the corresponding
serum urate half-life is ,4 days. As a steady state is established
within five half-lives, a 2-month treatment period should be
sufficient for evaluation of allopurinol treatment, even when we
take the allopurinol step-up dose scheme into account. In
addition, the decrease in sUr obtained with allopurinol 300 mg/day
in our study is comparable to that in previous studies using a
longer treatment period.32
Treatment success with benzbromarone was increased from
52% to 78% by titrating the dose up to 200 mg/day (p = 0.075).
The success rate was somewhat lower than expected from a
previous study, in which we found a 92% success rate with
benzbromarone 200 mg/day in 24 patients.7 This may be due to
some non-adherent patients because of a difference in trial
design (ie, exclusion of patients with low adherence to
allopurinol in a subsequent benzbromarone or probenecid
treatment group) and a lower tolerability rate. We did not
obtain any other data on the sUr-lowering effect and treatment
success of benzbromarone 200 mg/day.
Adherence to gout medication has been reported to be low in
general.33 In this study, we measured serum oxipurinol
concentrations in the allopurinol group. All patients had
measurable serum oxipurinol concentrations, and these
increased in each patient for whom the allopurinol dose was
increased; reported reference values for allopurinol 300 mg/day
are 5–15 mg/l, but higher values may be obtained.22 34 Poor
adherence by some patients in the benzbromarone group cannot
be excluded.
Table 2 Efficacy of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day after stage 1 and
stage 2*
Allopurinol Benzbromarone p Value
Stage 1 and 2 results (n = 27) (n = 23)
Dose (mg/day) 300–600 100–200
Treatment goal reached
sUr (0.30 mmol/l 21 (78%) 18 (78%) 1.00
95% CI 59–89% 58–90%
Treatment goal not reached
Withdrawn because of ADRs 2 (7%) 3 (13%) 0.62
sUr 0.31–0.36 mmol/l 2 (7%) 2 (9%) 1.00
sUr .0.36 mmol/l 2 (7%) 0 (0%) 0.34
Stage 1 results (n = 31) (n = 25)
Dose (mg/day) 300 100
Duration (months) 2.3 (0.8) 2.2 (0.7) 0.93
Range 1.5–4.9 1.6–3.2
Treatment goal reached
sUr (0.30 mmol/l 8 (26%) 13 (52%) 0.049
95% CI 12–45% 33–70%
Treatment goal not reached
Withdrawn because of ADRs 2 (7%) 3 (12%) 0.62
sUr 0.31–0.36 mmol/l 12 (39%) 2 (8%) 0.01
sUr .0.36 mmol/l 8 (27%) 7 (28%) 1.00
sUr reached (mmol/l) 0.34 (0.08) 0.29 (0.08) –
Range 0.21–0.49 0.16–0.45
DsUr from baseline (%) 233 (13) 242 (15) 0.04
uUr (mmol/day) 2.2 (1.2) 4.4 (1.7) ,0.001
Range 0.5–6.1 1.5–8.4
UrCl (ml/min per 1.73 m2) 3.6 (1.5) 4.9 (2.2) ,0.001
Range 1.0–8.0 3.0–20.6
Serum oxipurinol (mg/l) 13.1 (10.4) – –
Range 3.9–51.3
Stage 2 results* (n = 17) (n = 7)
Dose (mg/day) 600 200
Duration (months) 2.5 (0.7) 2.3 (0.8) 0.71
Range 1.5–4.9 1.6–3.2
sUr reached (mmol/l) 0.27 (0.07) 0.28 (0.04) –
Range 0.18–0.38 0.23–0.35
DsUr from baseline (%) 249 (14) 246 (8) –
DsUr from stage 1 (%) 232 (16) 229 (6) –
uUr (mmol/day) 2.1 (1.0) 4.9 (2.2) –
Range 1.1–3.5 2.1–8.1
UrCl (ml/min per 1.73 m2) 4.3 (1.5) 10.3 (3.7) –
Range 2.0–6.6 4.6–15.3
Serum oxipurinol (mg/l) 17.0 (9.9) – –
Range 4.9–41.7
Data are number (%) or mean (SD) and range, unless stated otherwise.
*No statistical comparisons were performed for stage 2 results because of incomparable groups due to selection bias.
ADR, adverse drug reaction; sUr, serum urate concentration; UrCl, urate clearance; uUr, urate excreted in urine.
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In this study, all patients had been referred to a rheumatol-
ogist, which may have introduced bias to inclusion of patients
with more severe gout. Better results may be obtained in
patients with less severe gout and lower baseline sUr.
Allopurinol of different (generic) brands was used, which may
have increased the variation in results. In the Netherlands, the
requirement for bio-equivalence is that the 90% CI must be
within 80–125% of the reference value.
The target sUr is still a matter of debate.35 In the recent
EULAR recommendations, a less strict target sUr of
(0.36 mmol/l was proposed for gout treatment in general,
but, in the case of severe gout, the treatment target may be set
lower.1 With a treatment goal of sUr of (0.36 mmol/l,
treatment successes would be 85% for allopurinol and 87% for
benzbromarone.
The tolerability rates found for allopurinol and benzbromar-
one did not differ significantly from data in other studies. All
adverse drug reactions reported for allopurinol and benzbro-
marone occurred in stage 1, and these reactions have been
described previously.11–13 36 37 Starting sUr-lowering treatment
can cause gout flares because of mobilisation of urate related to
the rapid decline in sUr. One patient developed generalised
exanthema after starting allopurinol at a dose of 100 mg/day,
and one patient developed exfoliative dermatitis during stage 1.
No hepatitis, defined as grade 2, 3 or 4 liver enzyme increases,
was seen with allopurinol or benzbromarone during the study
period. Severe hepatotoxicity caused by benzbromarone is seen
in rare cases, and has led to withdrawal of benzbromarone in
many countries. A mechanism for this hepatotoxicity was
recently reported.38 Patients with high renal urate clearances, eg,
from using uricosuric drugs, have an increased risk of urate
nephrolithiasis. Therefore, benzbromarone is relatively contra-
indicated in patients with normal renal urate clearances. In our
group of patients receiving benzbromarone, no urate nephro-
pathy, nephrolithiasis or urolithiasis was reported, and no
nephropathy was found on calculating creatinine clearances
before and after treatment.
This study was conducted in patients with a cCrCl >50 ml/
min. Results cannot be extrapolated to patients with cCrCl
,50 ml/min, because (1) the allopurinol dose should then be
adjusted to renal function, and (2) the efficacy of benzbromar-
one falls gradually with decreasing renal function to inefficacy
in the presence of cCrCl ,25 ml/min.39
We used sUr as a surrogate variable for clinical success.
Previous studies have found that the sUr attained is inversely
related to prevention of recurring gout flares and to the speed of
size reduction of tophi.15–19 Therefore, sUr is considered an
important variable in clinical practice for evaluating the success
of sUr-lowering treatment for gout in the long term.
There are few therapeutic options available for lowering sUr
to target levels other than the drugs used in this study. The
uricosuric drug, sulfinpyrazone, is not widely used because of its
adverse effects profile.39 Probenecid was found to be less
effective and less well tolerated than benzbromarone.7
Febuxostat, a novel xanthine oxidase inhibitor, has been found
to be more effective than allopurinol;32 however, the allopurinol
dose used for comparison was fixed at 300 mg/day.40 On the
other hand, febuxostat may prove beneficial in patients with
diminished renal function, as it is not renally excreted. A higher
allopurinol dose (eg, 600 mg/day) in the above comparative
study may have given similar end point results for allopurinol
and febuxostat.
Another sUr-lowering drug under development is pegylated
uricase, aimed at patients who are unresponsive to current sUr-
lowering treatments. As combination therapy of allopurinol and
a uricosuric drug (benzbromarone or probenecid) produces
additional lowering of sUr, this may also be a beneficial option.41
The impact of gout on work absence and productivity is
substantial, so pharmaco-economic studies on the newer and
older (out-of-patent) drugs, such as allopurinol and benzbro-
marone, are necessary.42
CONCLUSIONS
In patients with gout and renal function defined as cCrCl
>50 ml/min, increasing the allopurinol dose up to 600 mg/day
and benzbromarone dose up to 200 mg/day produces greater
treatment success (both 78% successful in attaining the target
sUr of (0.30 mmol/l). No significant differences in treatment
success were found between allopurinol and benzbromarone
Figure 2 Box plot diagram of serum urate concentrations (sUr) at
baseline and after stage 1 and stage 2 treatment with allopurinol and
benzbromarone. Results are depicted in two groups for each drug:
patients who completed stage 1 treatment and patients who completed
stage 2. o, outlying value; dotted line, target sUr.







Number of patients with ADR 2 (7%)/2 (7%) 3(12%)/5 (20%)
95% CI 1–22%/1–22% 3–31%/7–40%
Type of ADR
Dizziness and flushing –/– 1 (4%)/1 (4%)
Gastrointestinal –/– 2 (8%)/2 (8%)
Hepatitis* –/– –/–
Gout flares –/– –/1 (4%)
INR increase –/– –/1 (4%)
Rash/skin reactions 2 (7%)/2 (7%) –/–
Severe skin reactions –/– –/–
ADRs expressed as ADR leading to withdrawal (n (%))/total ADRs (n (%)) reported;
one patient could report more than one ADR.
*Grade 2, 3 or 4 liver enzyme increases.
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after the dose increase, and the increased dose was well
tolerated for both drugs.
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